NVO
Novo Nordisk A/S
NVO trails on the overall score without a compensating advantage in the available component scores.
RDNT
RadNet, Inc.
RDNT has the edge over NVO overall, supported by stronger fundamentals and lower modeled downside.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
RDNT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Healthy | |
| Stable |
RDNT's revenue and cash flow are currently healthy, and its balance sheet is stable, but its profitability is under pressure.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
RDNT PE Valuation
RDNT has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
RDNT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Stable | |
| Limited | |
| Low |
RDNT has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over RDNT on earnings quality, reporting a profit while its opponent remains loss making.
RDNT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.67 | — |
| Q3 2026 | -$0.28 | -$0.11 |
| Q2 2026 | -$0.26 | -$0.06 |
| Q1 2026 | -$0.17 | +$0.26 |
| Q4 2025 | -$0.25 | -725% |
| Q3 2025 | -$0.17 | -$0.17 |
| Q2 2025 | -$0.20 | -195% |
| Q1 2025 | -$0.43 | -216% |
| Q4 2024 | $0.04 | -20% |
RDNT is still losing money, but less than at its worst: $0.28 per share over the past year, against $0.43 at its worst in early 2025.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over RDNT on profitability, with a higher operating margin.
RDNT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $638.3M | +22% |
| Q2 2026 | $622.7M | +25% |
| Q1 2026 | $575.6M | +22% |
| Q4 2025 | $547.7M | +15% |
| Q3 2025 | $522.9M | +13% |
| Q2 2025 | $498.2M | +8.4% |
| Q1 2025 | $471.4M | +9.2% |
| Q4 2024 | $477.1M | +13% |
RDNT's revenue has grown year over year every quarter since late 2020: $638M last quarter, up 22% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 4.7% | -0.5 points |
| Q2 2026 | 6.3% | +0.1 points |
| Q1 2026 | -4.2% | +1 points |
| Q4 2025 | 5.1% | -0.1 points |
| Q3 2025 | 5.2% | -2.1 points |
| Q2 2025 | 6.2% | -1.4 points |
| Q1 2025 | -5.1% | -7.7 points |
| Q4 2024 | 5.1% | -0.7 points |
RDNT's operating margin was 4.7% last quarter, down 0.5 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over RDNT on cash flow, with more consistent year-over-year improvement.
RDNT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $35.1M | +$42.7M |
| Q2 2026 | $37.8M | -44% |
| Q1 2026 | $9M | +$16.4M |
| Q4 2025 | $33.1M | +$33.5M |
| Q3 2025 | -$7.6M | -147% |
| Q2 2025 | $67.4M | -2.8% |
| Q1 2025 | -$7.4M | +$33M |
| Q4 2024 | -$377K | -101% |
RDNT generated $115M in free cash flow over the past year, up 121% from the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over RDNT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
RDNT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +443K shares |
| 1 year | +2.3% | +1.8M shares |
| 3 years | +15% | +10.4M shares |
| 5 years | +47% | +25.4M shares |
| Available history | +57% | +28.9M shares |
RDNT has 79M diluted shares, up 2.3% from a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO has the edge over RDNT on leverage, with a lower net debt burden relative to earnings.
RDNT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.3x | Moderate |
| Q2 2026 | 2.5x | Moderate |
| Q1 2026 | 2.8x | Moderate |
| Q4 2025 | 1.5x | Healthy |
| Q3 2025 | 1.4x | Healthy |
| Q2 2025 | 1.3x | Healthy |
| Q1 2025 | 1.4x | Healthy |
| Q4 2024 | 1.1x | Healthy |
RDNT's net debt is about 2.3 years of its operating earnings (EBITDA), up from 1.4 years a year ago.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
RDNT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 60.3 | Neutral |
| Stochastic | 65.1 | Neutral |
RDNT's weekly RSI is 60 (neutral) and its Stochastic is 65 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
RDNT PE vs Healthcare Sector
| Metric | RDNT | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
RDNT has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
RDNT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $72.0 | 5.6% above |
| 20 week MA | $71.2 | 6.8% above |
| 50 week MA | $66.8 | 14% above |
| 100 week MA | $65.1 | 17% above |
| 200 week MA | $54.2 | 40% above |
RDNT has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
RDNT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $19.9 | $18.7 | -5.8% |
| 2021 | $18.7 | $30.4 | +62% |
| 2022 | $30.4 | $18.9 | -38% |
| 2023 | $18.9 | $34.8 | +84% |
| 2024 | $34.8 | $71.3 | +105% |
| 2025 | $71.3 | $73.2 | +2.6% |
| 2026 YTD | $73.2 | $76.0 | +4% |
RDNT has the edge over NVO on returns for 2026, with the stronger performance.